Drug Trial Radar · NCT05098132
Study of STK-012 Alone and With Other Treatments in Patients With Advanced Lung Cancer and Other Cancers
Last checked: Nov 19, 2026Latest source record: Oct 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
364
Planned (sponsor's estimate)
Start
Jan 25, 2022
Primary completion
Jan 2029
Study completion Jan 2029
Sponsor
- Lead sponsor
- SynthekineIndustry
- Sponsor type
- Industry
- Collaborators
- Merck Sharp & Dohme LLC
- First posted
- Oct 28, 2021
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a phase 1/2, multicenter, open-label study. The phase 1 portion is a dose escalation and expansion study of STK-012 as monotherapy and in combination therapy in patients with selected advanced solid tumors. The phase 2 portion is a randomized study of STK-012 in combination with standard of care (SoC) pembrolizumab, pemetrexed, and carboplatin versus SoC, in patients with first line, PD-L1 negative or STK11 mutated, non-squamous, non-small cell lung cancer.
Conditions
- Advanced Solid Tumor
- Non Small Cell Lung Cancer
- Untreated Advanced NSCLC
- 1st Line NSCLC
Interventions
STK-012Drug
Engineered Interleukin-2 (IL-2) selective for antigen activated T cells
pembrolizumab KEYTRUDA®Drug
anti-PD-1 monoclonal antibody
pemetrexedDrug
chemotherapy
carboplatinDrug
chemotherapy
Primary outcomes
What the sponsor says the trial is designed to measure.
- Phase 1a: Treatment emergent adverse events (TEAEs)Time frame: From 1st dose of study treatment through 90 days after last dose
- Phase 1a: Serious adverse events (SAEs)Time frame: From 1st dose of study treatment through 90 days after last dose
- Phase 1a: Dose limiting toxicities (DLTs)Time frame: Cycle 1, Days 1 through 21
- Phase 1a: DeathsTime frame: From 1st dose of study treatment until death, up to 4 years
- Phase 1b: TEAEs at the RP2DTime frame: From 1st dose of study treatment through 90 days after last dose
- Phase 1b: SAEs at the RP2DTime frame: From 1st dose of study treatment through 90 days after last dose
- Phase 1b: Deaths at the RP2DTime frame: From 1st dose of study treatment until death, up to 4 years
- Phase 2: Overall response rate (ORR) in Arm A versus Arm CTime frame: From randomization until disease progression or death, or the last evaluable assessment in the absence of progression, up to 4 years
Locations
60 sites in 6 countries. Site status is shown where the registry gives one.
University of Arizona Cancer Center
Tucson, Arizona · Recruiting
Beverly Hills Cancer Center
Beverly Hills, California · Recruiting
Providence Medical Foundation
Fullerton, California · Recruiting
UC San Diego Moores Cancer Center
La Jolla, California · Active not recruiting
Cedars Sinai
Los Angeles, California · Recruiting
Hoag Memorial Hospital Presbyterian
Newport Beach, California · Recruiting
UCLA Hematology/Oncology - Santa Monica
Santa Monica, California · Recruiting
Yale New Haven Hospital, Yale Cancer Center
New Haven, Connecticut · Recruiting
Georgetown University
Washington D.C., District of Columbia · Recruiting
Mayo Jacksonville
Jacksonville, Florida · Recruiting
Winship Cancer Institute, Emory University
Atlanta, Georgia · Recruiting
University of Chicago
Chicago, Illinois · Recruiting
University of Maryland
Baltimore, Maryland · Recruiting
Massachusetts General Hospital
Boston, Massachusetts · Recruiting
Beth Israel Deaconess Medical Center
Boston, Massachusetts · Recruiting
Dana-Farber Cancer Institute
Boston, Massachusetts · Recruiting
Mayo Rochester
Rochester, Minnesota · Recruiting
HealthPartners Cancer Center at Regions Hospital
Saint Paul, Minnesota · Recruiting
Northwell Health
Lake Success, New York · Recruiting
NYU Langone Health
New York, New York · Recruiting
Columbia University Irving Medical Center
New York, New York · Active not recruiting
Memorial Sloan-Kettering Cancer Center
New York, New York · Recruiting
Duke Cancer Center
Durham, North Carolina · Active not recruiting
University Hospitals Cleveland
Cleveland, Ohio · Recruiting
The James Cancer Hospital and Solove Research Institute
Columbus, Ohio · Recruiting
Providence Cancer Institute
Portland, Oregon · Recruiting
Fox Chase Cancer Center
Philadelphia, Pennsylvania · Recruiting
UPMC Hillman Cancer Center
Pittsburgh, Pennsylvania · Terminated
Baptist Memorial Hospital Cancer Center
Memphis, Tennessee · Active not recruiting
Sarah Cannon Research Institute - Nashville
Nashville, Tennessee · Active not recruiting
Renovatio Clinical
El Paso, Texas · Withdrawn
Oncology Consultants
Houston, Texas · Recruiting
Renovatio Clinical
The Woodlands, Texas · Withdrawn
NEXT Virginia
Fairfax, Virginia · Recruiting
Northwest Medical Specialties
Tacoma, Washington · Active not recruiting
LTD High Technology Hospital Medcenter
Batumi, Georgia · Recruiting
Caraps Medline, Ltd (JSC VIAN)
Tbilisi, Georgia · Recruiting
Institute of Clinical Oncology (ICO)
Tbilisi, Georgia · Recruiting
Israel Georgian Medical Research Clinic Healthycore
Tbilisi, Georgia · Recruiting
START Dublin
Dublin, Ireland · Recruiting
Showing 40 of 60 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.